Linker Pharmaceuticals ApS: Financial statements 2025
CVR: 44308622
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Linker Pharmaceuticals ApS (CVR 44308622) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -341,305 and a net result of DKK -268,417. Equity in the 2025 report amounted to DKK 57,244. The solvency ratio was 53.3%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -341,305
- Profit/Loss
- DKK -268,417
- Equity
- DKK 57,244
- Total Assets
- DKK 107,363
- Employees
- 2
Official annual report
How creditworthy is Linker Pharmaceuticals ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of August 19, 2025, Resistance Oncology ApS is registered as an owner of Linker Pharmaceuticals ApS with an ownership share of 100%.
Linker Pharmaceuticals ApS has published its interim report for the period September 15, 2023 – December 31, 2024.
About Linker Pharmaceuticals ApS
Linker Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Nils Aage Brünner and Kasper Pasternak Jørgensen. The company is owned by Resistance Oncology ApS. According to the 2025 annual report, the company had an average of 2 employees. In 2025, the company reported a gross profit of DKK -341,305 and a net result of DKK -268,417. Equity in the 2025 report amounted to DKK 57,244.